WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO aims at promoting scientific excellence in fundamental life sciences research and translating scientific achievements in medical, pharmaceutical and veterinary biotechnology applications.
In a study lead by Prof. Michel Georges (Welbio investigator at GIGA-Ulg), scientists examined the genome of 67,852 individuals and applied three statistical methods to zoom in on which genetic variants were actively implicated in the Inflammatory bowel disease. The results of this study were published in Nature.
WELBIO is pleased to announce that Prof. Decio Eizirik, WELBIO investigator at the Université Libre de Bruxelles, has been invited to present the keynote Ernst Knobil Lecture at the 38th World Congress of the International Union of Physiological Sciences (IUPS-2017), to be held in Rio de Janeiro, Brazil, from August 1 to August 5, 2017.
New progress in treating breast cancer. Prof. Raspé and Roger’s team (WELBIO - IRIBHM – ULB), in collaboration with the Institut Jules Bordet, identified the activating phosphorylation on T172 of CDK4, as the most relevant biomarker to predict the response to palbociclib. The results of this study have been published in EMBO Molecular Medicine.